Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study

Current Medical Research and Opinion
Masatoshi KikuchiRyutaro Ishii

Abstract

A 28-week, randomized, placebo-controlled study was performed to evaluate efficacy and tolerability of rosiglitazone in Japanese type 2 diabetes patients. 373 patients were randomized to rosiglitazone (4-8 mg/day), pioglitazone (15-45 mg/day) or placebo. Agents were titrated to maximum doses at fixed time points in a pre-defined manner. Primary endpoints were superiority of each active treatment compared to placebo in HbA(1c) at week 16, and non-inferiority between active agents in HbA(1c) at week 28, based on a -0.45% margin. At week 16, improvements versus placebo were observed with rosiglitazone 4 mg/day (-0.96%, p < 0.001) and pioglitazone 30 mg/day (-1.26%, p < 0.001). At week 28, rosiglitazone and pioglitazone were associated with significant changes from baseline of -0.94% and -1.35%, respectively and rosiglitazone produced statistically and clinically significant improvement versus placebo (-1.29%, CI: -1.62, -0.97). Pioglitazone also showed significant improvement versus placebo (-1.64%, CI: -1.96, -1.31). Non-inferiority of rosiglitazone (4-8 mg/day) to pioglitazone (30-45 mg/day) was not demonstrated (treatment-difference: -0.41%, 95% CI: -0.64, -0.18). More patients treated with pioglitazone were withdrawn from the ...Continue Reading

References

Jul 24, 2002·Diabetologia·A LieblUNKNOWN ODE-2 Advisory Board
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Dec 29, 2004·Diabetes Research and Clinical Practice·Yoo Mee KimHyun Chul Lee
May 14, 2005·Diabetes Research and Clinical Practice·Stewart B HarrisSusan Webster-Bogaert
Oct 21, 2005·International Journal of Clinical Practice·S Del PratoUNKNOWN Global Partnership for Effective Diabetes Management
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jan 16, 2007·European Journal of Internal Medicine·J W F Elte, J F Blicklé
May 9, 2007·Journal of Atherosclerosis and Thrombosis·Tamio TeramotoYasushi Saito
Feb 12, 2008·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Kai-Min ChuCheng-Huei Hsiong
Jul 17, 2008·Current Medical Research and Opinion·Mark Peyrot, Richard R Rubin
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil

❮ Previous
Next ❯

Citations

Mar 17, 2015·Current Medical Research and Opinion·Keith C Ferdinand, Samar A Nasser
Aug 24, 2018·Biology of Reproduction·Hamid-Reza Kohan-GhadrSascha Drewlo
Jul 2, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yannick FotioRoberto Ciccocioppo
Mar 7, 2021·International Journal of Biological Macromolecules·Huashan GaoYuanhao Qiu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.